JPS6241500B2 - - Google Patents
Info
- Publication number
- JPS6241500B2 JPS6241500B2 JP13864479A JP13864479A JPS6241500B2 JP S6241500 B2 JPS6241500 B2 JP S6241500B2 JP 13864479 A JP13864479 A JP 13864479A JP 13864479 A JP13864479 A JP 13864479A JP S6241500 B2 JPS6241500 B2 JP S6241500B2
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen atom
- group
- indole derivative
- lower alkyl
- acylated indole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000002475 indoles Chemical class 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 claims description 2
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 229940127218 antiplatelet drug Drugs 0.000 claims description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000000243 solution Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 10
- 238000004220 aggregation Methods 0.000 description 10
- 230000002776 aggregation Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 9
- 210000004623 platelet-rich plasma Anatomy 0.000 description 7
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- RMBLTWUTZAFABA-XVSDJDOKSA-N (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoic acid;sodium Chemical compound [Na].CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O RMBLTWUTZAFABA-XVSDJDOKSA-N 0.000 description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- RNOIDXRVDBHIGA-UHFFFAOYSA-N [1-(1-hydroxypropan-2-yl)indol-3-yl]-phenylmethanone Chemical compound C12=CC=CC=C2N(C(CO)C)C=C1C(=O)C1=CC=CC=C1 RNOIDXRVDBHIGA-UHFFFAOYSA-N 0.000 description 2
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000010413 mother solution Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- -1 (1-hydroxy-2-propyl)indole Chemical compound 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010050902 Postoperative thrombosis Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000008394 flocculating agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940057847 polyethylene glycol 600 Drugs 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- DDMGAAYEUNWXSI-XVSDJDOKSA-M sodium;(5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate Chemical compound [Na+].CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O DDMGAAYEUNWXSI-XVSDJDOKSA-M 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13864479A JPS5663960A (en) | 1979-10-29 | 1979-10-29 | Acylated indole derivative and platelet coagulation inhibitor containing the same as active constituent |
| EP19800302180 EP0022634B1 (en) | 1979-06-28 | 1980-06-27 | Acylated indole derivatives, processes for their preparation and pharmaceutical compositions and drugs comprising them |
| DE8080302180T DE3062613D1 (en) | 1979-06-28 | 1980-06-27 | Acylated indole derivatives, processes for their preparation and pharmaceutical compositions and drugs comprising them |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13864479A JPS5663960A (en) | 1979-10-29 | 1979-10-29 | Acylated indole derivative and platelet coagulation inhibitor containing the same as active constituent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5663960A JPS5663960A (en) | 1981-05-30 |
| JPS6241500B2 true JPS6241500B2 (enrdf_load_stackoverflow) | 1987-09-03 |
Family
ID=15226817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP13864479A Granted JPS5663960A (en) | 1979-06-28 | 1979-10-29 | Acylated indole derivative and platelet coagulation inhibitor containing the same as active constituent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5663960A (enrdf_load_stackoverflow) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS579761A (en) * | 1980-06-20 | 1982-01-19 | Teijin Ltd | Acylated indole derivative, its preparation, and pharmaceutical composition containing said compound as active component |
| JPH0751560B2 (ja) * | 1983-09-28 | 1995-06-05 | 日本臓器製薬株式会社 | 新規アシルインドール誘導体及び該化合物を含有する医薬組成物 |
| JPH0647574B2 (ja) * | 1984-08-11 | 1994-06-22 | 日本臓器製薬株式会社 | 新規アシルインド−ル誘導体及び該化合物を有効成分として含有する血小板凝集抑制剤 |
-
1979
- 1979-10-29 JP JP13864479A patent/JPS5663960A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5663960A (en) | 1981-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU725949B2 (en) | Antithrombotic antiatherogenic pharmaceutical composition comprising a thienopyridine derivative and an HMG-CoA-reductase inhibitor | |
| JPH02268178A (ja) | ３―ホルミルアミノ―７―メチルスルホニルアミノ―６―フェノキシ―４ｈ―１―ベンゾピラン―４―オンまたはその塩を含有する抗炎症製剤 | |
| RU2250103C2 (ru) | ПРИМЕНЕНИЕ (R)-АРИЛПРОПИОНОВЫХ КИСЛОТ ДЛЯ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЛЮДЕЙ И ЖИВОТНЫХ, НА КОТОРЫЕ МОЖНО ОКАЗЫВАТЬ ТЕРАПЕВТИЧЕСКОЕ ВОЗДЕЙСТВИЕ ПУТЕМ ИНГИБИРОВАНИЯ АКТИВАЦИИ NF-κВ | |
| PT1488808E (pt) | Medicamentos para doenças glomerulares | |
| JPS6241500B2 (enrdf_load_stackoverflow) | ||
| JPH0788307B2 (ja) | デイルチアゼムおよびアスピリンを主成分とする血小板凝集阻害剤 | |
| EP0379579A1 (en) | Pharmaceutical composition having improved releasability | |
| EP0001503B1 (en) | Antithrombotic compositions containing benzisothiazolones | |
| EP0000254B1 (en) | Antithrombotic 2-(gamma-(1-piperidinyl)propyl)1,2-benzisothiazol 3-one, its pharmaceutically acceptable acid addition salts, their preparation and their compositions | |
| JPS6140647B2 (enrdf_load_stackoverflow) | ||
| JPS63208520A (ja) | ピラジン誘導体を含有する血小板凝集抑制剤 | |
| JPH02255624A (ja) | 血小板凝集抑制剤 | |
| JP2515114B2 (ja) | 血小板凝集抑制剤 | |
| US3852454A (en) | Treatment of rheumatoid arthritis | |
| US3810991A (en) | A method of inducing fibrinolysis | |
| US4182768A (en) | Prophylaxis or treatment of thromboses and inhibition of platelet aggregation in human blood | |
| US6129932A (en) | Compositions for inhibiting platelet aggregation | |
| US3749781A (en) | Pharmaceutical composition and method of treatment | |
| JPS6141895B2 (enrdf_load_stackoverflow) | ||
| JPH04145023A (ja) | ヒダントイン誘導体を有効成分とする循環器系疾患の予防及び治療剤 | |
| JPS6261568B2 (enrdf_load_stackoverflow) | ||
| JPS61277617A (ja) | 坑血小板凝集剤 | |
| JP4248780B2 (ja) | 過酸化脂質低下剤組成物 | |
| US3784695A (en) | Production of an hypotensive effect with esters of gallic acid | |
| JPH09151131A (ja) | 抗メチシリン耐性黄色ブドウ球菌感染症剤 |